
|Videos|November 4, 2021
Controlling ACE and ARB Dosing Can Benefit Treatment of Chronic Kidney Disease
Chi Chu, MD, an assistant professor in the division of nephrology at the University of California San Francisco, discusses how ACE and ARB therapies can be applied to chronic kidney disease, and the benefits of controlling the dosage.
Advertisement
In a Pharmacy Times® interview, Chi Chu, MD, an assistant professor in the division of nephrology at the University of California San Francisco, spoke about his 2021 ASN Kidney Week presentation on the submaximal dose of angiotensin converting enzyme (ACE) inhibitor and angiotensin II receptor blockers (ARB) for individuals with proteinuria.
He discussed how ACE and ARB therapies can be applied to chronic kidney disease, and the benefits of controlling the dosage.
Advertisement
Latest CME
Advertisement
Advertisement
Trending on Pharmacy Times
1
FDA Approves Enlicitide, the First Oral PCSK9 Inhibitor for High Cholesterol
2
Cyclosporiasis Cases Reach 5100: Investigators Zero In On Lettuce, Possible Taco Bell Link
3
Patient-Reported Outcomes, Machine Learning May Predict Breast Cancer Recurrence Earlier
4
Subcutaneous Olanzapine in Schizophrenia: Expanding the Utility of a Proven Therapy
5










































































































